Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Mol Cancer
; 21(1): 84, 2022 03 25.
Article
in En
| MEDLINE
| ID: mdl-35337339
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Triple Negative Breast Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Mol Cancer
Year:
2022
Document type:
Article